Restless legs syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
(3 intermediate revisions by one other user not shown) | |||
Line 4: | Line 4: | ||
{{CMG}} {{AE}} {{MMJ}} | {{CMG}} {{AE}} {{MMJ}} | ||
==Medical Therapy== | ==Medical Therapy== | ||
==Overview== | ==Overview== | ||
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3]. | Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
*Pharmacologic medical therapy is recommended among patients with persistent or moderate to severe symptoms of restless legs syndrome. | In patients with mild symptoms of restless legs syndrome, no treatment may be required, although all patients should be screened for [[Iron deficiency anemia|iron deficiency]].<ref name="pmid24363103" /> | ||
*Pharmacologic medical therapies for restless legs syndrome include dopamine agonists, alpha-2-delta calcium channel ligands and opioids. | *Pharmacologic medical therapy is recommended among patients with persistent or moderate to severe symptoms of restless legs syndrome.<ref name="pmid24363103" /> | ||
*Pharmacologic medical therapies for restless legs syndrome include [[dopamine agonists]], alpha-2-delta calcium channel ligands and [[opioids]].<ref name="pmid24363103">{{cite journal| author=Comella CL| title=Treatment of restless legs syndrome. | journal=Neurotherapeutics | year= 2014 | volume= 11 | issue= 1 | pages= 177-87 | pmid=24363103 | doi=10.1007/s13311-013-0247-9 | pmc=3899490 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24363103 }} </ref> | |||
=== | |||
* | * The treatment of restless legs syndrome must be individualized to each patient.<ref name="pmid24363103" /> | ||
* In patients with mild symptoms, no treatment is required.<ref name="pmid24363103" /> | |||
* | |||
=== Treatment of restless legs syndrome === | |||
* Preferred regimen (1): [[pramipexole]]<ref name="pmid11054156">{{cite journal| author=Montplaisir J, Denesle R, Petit D| title=Pramipexole in the treatment of restless legs syndrome: a follow-up study. | journal=Eur J Neurol | year= 2000 | volume= 7 Suppl 1 | issue= | pages= 27-31 | pmid=11054156 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11054156 }} </ref> | |||
** Treatment with [[pramipexole]] is started at a dosage of 0.25 mg per day, and progressively increase until the optimal therapeutic effect is obtained. | |||
* Preferred regimen (2): [[Ropinirole]]<ref name="pmid19412490">{{cite journal| author=Kushida CA| title=Ropinirole for the treatment of restless legs syndrome. | journal=Neuropsychiatr Dis Treat | year= 2006 | volume= 2 | issue= 4 | pages= 407-19 | pmid=19412490 | doi= | pmc=2671939 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19412490 }} </ref> | |||
**It is important to take [[ropinirole]] prior to symptom onset. | |||
**For daily RLS, [[ropinirole]] may be started at 0.25 mg per day at 2 hours before RLS symptom onset, and then increased by 0.25 mg every 2 to 3 days until symptom relief is achieved (Silber et al 2004). Starting dose should be individualized based on RLS severity and age. | |||
**The effective dose for [[ropinirole]] is typically 2 mg or less. | |||
**Some patients may require doses as high as 6 mg/day. | |||
* Preferred regimen (3): [[Carbidopa/levodopa]] 25/100 mg PO daily at bedtime<ref name="pmid24363103">{{cite journal| author=Comella CL| title=Treatment of restless legs syndrome. | journal=Neurotherapeutics | year= 2014 | volume= 11 | issue= 1 | pages= 177-87 | pmid=24363103 | doi=10.1007/s13311-013-0247-9 | pmc=3899490 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24363103 }} </ref> | |||
* Alternative regimen (1): [[Gabapentin]] 300–1200 mg daily about 1 h before bedtime.<ref name="pmid24363103">{{cite journal| author=Comella CL| title=Treatment of restless legs syndrome. | journal=Neurotherapeutics | year= 2014 | volume= 11 | issue= 1 | pages= 177-87 | pmid=24363103 | doi=10.1007/s13311-013-0247-9 | pmc=3899490 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24363103 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Sleep disorders]] | [[Category:Sleep disorders]] | ||
[[Category:Syndromes]] | [[Category:Syndromes]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 23:58, 29 July 2020
Restless legs syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Restless legs syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Restless legs syndrome medical therapy |
Risk calculators and risk factors for Restless legs syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Medical Therapy
Overview
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
Medical Therapy
In patients with mild symptoms of restless legs syndrome, no treatment may be required, although all patients should be screened for iron deficiency.[1]
- Pharmacologic medical therapy is recommended among patients with persistent or moderate to severe symptoms of restless legs syndrome.[1]
- Pharmacologic medical therapies for restless legs syndrome include dopamine agonists, alpha-2-delta calcium channel ligands and opioids.[1]
- The treatment of restless legs syndrome must be individualized to each patient.[1]
- In patients with mild symptoms, no treatment is required.[1]
Treatment of restless legs syndrome
- Preferred regimen (1): pramipexole[2]
- Treatment with pramipexole is started at a dosage of 0.25 mg per day, and progressively increase until the optimal therapeutic effect is obtained.
- Preferred regimen (2): Ropinirole[3]
- It is important to take ropinirole prior to symptom onset.
- For daily RLS, ropinirole may be started at 0.25 mg per day at 2 hours before RLS symptom onset, and then increased by 0.25 mg every 2 to 3 days until symptom relief is achieved (Silber et al 2004). Starting dose should be individualized based on RLS severity and age.
- The effective dose for ropinirole is typically 2 mg or less.
- Some patients may require doses as high as 6 mg/day.
- Preferred regimen (3): Carbidopa/levodopa 25/100 mg PO daily at bedtime[1]
- Alternative regimen (1): Gabapentin 300–1200 mg daily about 1 h before bedtime.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Comella CL (2014). "Treatment of restless legs syndrome". Neurotherapeutics. 11 (1): 177–87. doi:10.1007/s13311-013-0247-9. PMC 3899490. PMID 24363103.
- ↑ Montplaisir J, Denesle R, Petit D (2000). "Pramipexole in the treatment of restless legs syndrome: a follow-up study". Eur J Neurol. 7 Suppl 1: 27–31. PMID 11054156.
- ↑ Kushida CA (2006). "Ropinirole for the treatment of restless legs syndrome". Neuropsychiatr Dis Treat. 2 (4): 407–19. PMC 2671939. PMID 19412490.